Agenus Inc. AGEN is a Lexington, MA-based development-stage company focused on developing immunotherapies for cancer and other diseases.
With no approved products in its portfolio, Agenus’ revenues consist of fees earned under license agreements with its partners. Meanwhile, investor focus remains on updates on pipeline progress apart from the usual top-line numbers.
Agenus has a disappointing earnings track record with the company missing estimates in all of the last four trailing quarters with an average negative surprise of 65%.
Currently, Agenus has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported a loss of 18 cents in the fourth quarter of 2015, in line with our consensus estimate.
Revenue: Revenues, however, surpassed expectations. Agenus posted revenues of $7.6 million, compared to our consensus estimate of $5 million.
Key Stats: Agenus’ efforts for the development of its pipeline are pleasing. Agenus received a major boost when the FDA cleared its IND application for AGEN1884 and a second CPM antibody, INCAGN01876, for which it has a partnership with Incyte. The company is progressing with the development of its Prophage Series vaccine, which is scheduled to enter into a phase III study for newly-diagnosed GBM in the second half of 2016. Meanwhile, GlaxoSmithKline’s shingles vaccine candidat (HZ/su) containing Agenus’ QS-21 Stimulon adjuvant showed 90% overall efficacy against shingles versus placebo in a phase III efficacy study. Glaxo intends to file for its approval in the U.S., the EU and Japan in the second half of 2016.
Check back later for our full write up on Agenus report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AGENUS INC (AGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research